Medical Review Policy

Who medically reviews GLP1 One Rx content

Three named individuals are responsible for every piece of medical content on this site:

• Dr. Sam Saberian — Lead Medical Researcher. Lead author of the v3.0 six-pillar transparency rubric. Drafts provider reviews, clinical summaries, and editorial guides. Areas of focus: GLP-1 receptor agonist therapeutics, peptide pharmacology, telehealth pharmacy traceability standards (503A/503B, USP <797>).
• Alen A. Schwartz, MD — Medical Reviewer. Board-certified physician. Performs clinical accuracy review on every guide, provider review, and trial summary. Areas of clinical focus: GLP-1 / GIP receptor agonist therapeutics, obesity medicine, compounded sterile pharmacy oversight. All medication safety claims, contraindication disclosures, and dose-related claims are reviewed by Dr. Schwartz prior to publication.
• Julliana Edwards — Editor. Reviews and edits content for accuracy, clarity, and adherence to the published rubric methodology. Leads the corrections process.

The review workflow

1. Draft. Dr. Sam Saberian drafts content using sources from the Tier 1 / Tier 2 / Tier 3 source hierarchy (below). Every numeric claim has a footnote citation to a Tier 1 or Tier 2 source.
2. Medical review. Alen A. Schwartz, MD reads the draft and verifies: (a) drug class identification, (b) dosing schedule accuracy, (c) contraindication and AE disclosure, (d) FDA-approval status statements, (e) clinical trial citation accuracy (PMID and primary endpoint), (f) regulatory clarity (compounded vs FDA-approved framing). Comments are returned to the author for revision.
3. Author revision. Dr. Saberian addresses Dr. Schwartz's comments and returns the revised draft for confirmation.
4. Editorial review. Julliana Edwards performs final editing for clarity, structure, internal-link integrity, and rubric-alignment.
5. Publication. The page is published with a "Medically reviewed by Alen A. Schwartz, MD" attribution in the byline and a reviewedBy reference in the JSON-LD MedicalWebPage / Article schema.

Source hierarchy

Content is sourced from three tiers, with priority given to Tier 1:

• Tier 1 — Peer-reviewed clinical trials (NEJM, JAMA, Lancet, Annals); FDA databases (Orange Book, Drugs@FDA, 503B Outsourcing Facility Registration); FDA Drug Safety Communications; manufacturer prescribing information (USPI); USP General Chapters (USP <71>, <85>, <797>, <800>).
• Tier 2 — State pharmacy board records; LegitScript verification; Better Business Bureau (BBB); Trustpilot aggregate data; AMA, ASBP, OMA position statements; provider clinical protocols when publicly published.
• Tier 3 — Editorial test orders, structured patient interviews, social-media patient signal aggregation. Tier 3 sources are used only as context and never to support a primary clinical claim.

Review cadence

• Per-publication. Every new page is medically reviewed before publication.
• Monthly. Drug fact verification (FDA status, label expansions, recalls) across all 14 medication pages.
• Quarterly. Full methodology review and re-validation of the v3.0 rubric.
• Within 7 days. Updates following FDA Drug Safety Communications, new pivotal trial publications, regulatory enforcement actions affecting the GLP-1 / compounded GLP-1 class, or labeling changes.

What is reviewed

Medical review applies to all claims of the following types:

• Drug pharmacology — mechanism, half-life, receptor activity, metabolism, drug-drug interactions.
• Dosing — titration schedules, maintenance doses, dose-reduction triggers.
• Contraindications & warnings — absolute and relative contraindications, boxed warnings, populations at elevated risk (pregnancy, MEN-2, MTC family history, severe gastroparesis, pancreatitis history).
• Adverse events — frequency, severity, monitoring guidance.
• Clinical trial citation — trial name, PMID, primary endpoint, effect size, statistical confidence interval.
• FDA-approval status — brand vs compounded distinction, semaglutide-base vs salt-form distinction, compounded medications are not FDA-approved.
• Pharmacy oversight — 503A vs 503B distinction, USP testing standards, CoA availability.

Disclosures & integrity

• Independent. GLPONERX LLC is independent of any pharmaceutical manufacturer, telehealth provider, or compounding pharmacy.
• No paid placement. Providers cannot pay to appear in the directory or rank higher. Rankings are rubric-driven.
• Affiliate disclosure. Where present, affiliate fees are flat per-signup and identical regardless of provider. See the affiliate disclosure.
• Not medical advice. Content is educational. Information published here is not a substitute for individualized advice from a licensed clinician. Patients should never start, modify, or discontinue a prescription medication based on website content alone.

Corrections

If you identify a medical accuracy concern, email [email protected] with the page URL, the specific claim, and a Tier 1 or Tier 2 source supporting your concern. Response within 72 hours; warranted corrections published within 7 days, with a dated note in the corrections log.

Reviewer credentials

Alen A. Schwartz, MD is a board-certified physician. Clinical focus: GLP-1 receptor agonist therapeutics (semaglutide and tirzepatide), obesity medicine, and compounded sterile pharmacy oversight (USP <797>, 503A and 503B pathway distinctions). For verification, contact [email protected].